Eli Lilly announced a $27 billion investment to build four new U.S. manufacturing sites, bringing its total U.S. investments to over $50 billion.

The move, aligned with Trump’s reshoring policies, was unveiled at a Washington, D.C., event featuring Trump administration officials.

The sites will boost production of key drug ingredients, including those for its obesity and diabetes treatments Zepbound and Mounjaro, and create over 3,000 permanent jobs.

Eli Lilly also aims to expand beyond these drugs into cancer, Alzheimer’s, and other treatments, CNBC has reported.

The company opposes cheaper compounded versions of its drugs, emphasizing safety and regulatory concerns.

Written by B.C. Begley